Geneseeq Technology Inc.

🎄 Wishing all of you a Merry Christmas and a New Year filled with warmth and happiness. A big thank you to everyone who has been part of our journey this year. Let’s make 2025 even brighter! ✨ #Geneseeq #Holiday

B-cell acute lymphoblastic leukemia (B-ALL) remains the most prevalent hematologic malignancy in children and a leading cause of mortality, with management complicated by its heterogeneity and relapse risk. In a recent Geneseeq-collaborated study, the researchers investigated the molecular landscape of B-ALL. Minimal residual disease (#MRD) testing was performed using the Geneseeq Hemasalus™ panel. The results highlighted the potential of ctDNA and bone marrow profiling to provide critical prognostic insights for pediatric B-ALL management. Read more about this study: https://lnkd.in/gZeqqtff Learn more about Hemasalus™: https://lnkd.in/g3RuzJVk #pediatriconcology #ctDNA #nextgenerationsequencing #precisionmedicine #cancerresearch #hematology #leukemia

The FDA has just granted accelerated approval to a groundbreaking therapy, zenocutuzumab-zbco, for treating NSCLC and pancreatic adenocarcinoma harboring NRG1 fusions—a rare but actionable driver of cancer. This marks the first FDA approval of a systemic treatment specifically targeting NRG1 gene fusions in patients with NSCLC or pancreatic adenocarcinoma. At Genseeq, we are at the forefront of precision diagnostics, offering state-of-the-art testing solutions to detect NRG1 fusions and other actionable genetic alterations. Our GeneseeqPrime™ DNA panel and Pancarna™ RNA panel deliver comprehensive genomic profiling, enabling the identification of rare oncogenic drivers and unlocking new therapeutic opportunities for patients. Learn more about GeneseeqPrime™ and Pancarna™: https://lnkd.in/gwA8QkUW Read more about Genseeq's study on NRG1: https://lnkd.in/ga8cd5VQ #precisiononcology #NRG1fusions #GenseeqPrime #targetedtherapies #cancerdiagnostics

🎊 Exciting news! Geneseeq's EGFR/KRAS/MET Gene Mutation Detection Kit has entered China’s NMPA Special Review and Approval pathway for Innovative Medical Devices – a first for NGS liquid biopsy in China! 🥳 This kit identifies key tumor-driving mutations through ctDNA analysis, offering a non-invasive alternative to tissue testing. 🔥 Learn more about our liquid biopsy kit: https://lnkd.in/gn6CP4ER #NGS  #oncology #NMPA #precisionmedicine  #targetedtherapy  #Geneseeq

November 30 is Stomach Cancer Awareness Day. The risk of getting stomach cancer increases with age, with the average age of diagnosis being 68. It’s important to detect stomach cancer at an early stage, as localized stomach cancer has a 70% 5-year survival rate. Let’s come together to raise awareness and support those affected. Learn more about Stomach Cancer: Cancer.net Learn more about Geneseeq's solutions: https://lnkd.in/gKyWGP-Q #NGS  #oncology #precisionmedicine  #targetedtherapy  #Geneseeq #stomach

While blood cancers were among the earliest malignancies identified with clinically actionable genetic alterations, solid tumors like lung and breast cancers have dominated the spotlight in precision medicine advancements over the past decade. However, at the recent AMP annual meeting, pathologists and other experts highlighted the growing recognition of comprehensive genomic profiling (CGP) in hematology-oncology as a valuable diagnostic and therapeutic tool. Despite its promise, the adoption of CGP remains inconsistent, with reimbursement challenges persisting, particularly from commercial payors. Geneseeq has been offering compreshensive DNA/RNA panels for hematological tumors, which also show clinical benefit through our collaborations with oncologists. Read more about the AMP meeting: https://lnkd.in/gyaNBhp7... Read more about Geneseeq's study on hematological tumors: https://lnkd.in/gxw3ftxn https://lnkd.in/gZeqqtff Learn more about Geneseeq panel for hematological tumors: https://lnkd.in/gs2yTrKm #AMP #hematologicalcancers #precisiononcology #cancerresearch

The American Society of Hematology (#ASH) Annual Meeting is a leading event in the field of hematology, bringing together experts from around the globe to discuss advances in blood disorders research. This year, the ASH Annual Meeting will take place from December 7th to 10th, 2024, in San Diego, California. Geneseeq will deliver an oral presentation highlighting findings on CSF-ctDNA as a biomarker for predicting CNS relapse in DLBCL, supported by data from a large cohort study. In addition, Geneseeq will present five posters covering a diverse range of topics, including biomarkers, minimal residual diseases, cancer genomics, and therapeutic advancements for hematological malignancies. Oral (Abstract 576): Clinical Implications of CSF-Ctdna Positivity in Newly Diagnosed Diffuse Large B Cell Lymphoma in a Large Cohort 🔗 https://lnkd.in/gsVhi_-r Poster 1 (Abstract 1694): Improving Targeted Therapies in Primary CNS Lymphoma: Real-World Use of Cerebrospinal Fluid Circulating Tumor DNA for Monitoring 🔗 https://lnkd.in/gRJazKtZ Poster 2 (Abstract 1709): Clinical Implications of Ctdna-Based Minimal Residual Disease Detection in Newly Diagnosed Diffuse Large B-Cell Lymphoma 🔗 https://lnkd.in/gHkZvFzg Poster 3 (Abstract 1733): The ZR2-Minichop Study: Zanubrutinib, Lenalidomide, Rituximab, Cyclophosphamide, Vincristine, Epirubicin, and Prednisone in Elderly Patients with Previously Untreated Diffuse Large B-Cell Lymphoma 🔗 https://lnkd.in/gQF6Shz2 Poster 4 (Abstract 3071): Clinical Features and CSF-Ctdna Characteristics in Extranodal Natural Killer/T‐Cell Lymphoma Patients with Central Nervous System Involvement 🔗 https://lnkd.in/gWMxRBtn Poster 5 (Abstract: 4500): Preliminary Data on the Efficacy and Safety of Orelabrutinib Combined with Rituximab and Methotrexate (ORM Regimen) As First-Line Treatment for Primary Central Nervous System Lymphoma, and the Exploration of Cerebrospinal Fluid Ctdna Dynamic Monitoring 🔗 https://lnkd.in/gAQ4p2M5 #NGS #oncology #precisionmedicine #targetedtherapy #Geneseeq #Pancreatic #cancer #hematology #ctdna

We're at the AMP annual meeting! Schedule a meeting with us at AMP to discuss potential collaborations via info.toronto@geneseeq.com

Esophageal squamous cell carcinoma (#ESCC) is common in Eastern Asia and often isn't caught until it's quite advanced. Traditional treatments haven't been very effective. Recently, the Phase II NEXUS-1 trial (ChiCTR2100054327), a single-center, open-label trial, has been evaluating the antitumor activity and safety of definitive chemoradiotherapy (dCRT) followed by tislelizumab-based immunochemotherapy (iCT) as conversion therapy in patients with unresectable locally advanced ESCC. At Geneseeq, we’re proud to participate in the NEXUS-1 trial by utilizing the ShieldingULTRA™ and Radiotron™ panels to analyze genomic profiles and plasma-based biomarkers for prognosis. Through the dynamic monitoring of minimal residual disease (#MRD), the ability to predict treatment success and tailor personalized cancer therapies was significantly enhanced. 🔗 Read more about this study: https://lnkd.in/gp-ZwE8u 🔗 Learn more about Geneseeq ShieldingULTRA™ panel: https://lnkd.in/gmmUPQif 🔗 Learn more about Geneseeq Radiotron™ panel: https://lnkd.in/gcXVpn6n #CancerResearch #EsophagealCancer #PersonalizedMedicine #Genomics #HealthcareInnovation #NGS #oncology #Geneseeq #Esophagealsquamouscellcarcinoma #minimalresidualdisease

This year’s International Society of Liquid Biopsy (#ISLB2024) is just around the corner! At ISLB, Geneseeq and our collaborators from London Health Sciences Centrewill showcase a study that utilizes Geneseeq’s MRD panel (SHIELDING™ ULTRA) to analyze ctDNA in stage I/IIA NSCLC patients before and after stereotactic ablative radiotherapy (SABR). Learn more about the study (PP01.82): https://lnkd.in/efmMeAQu Learn more about our MRD panel: https://lnkd.in/gmmUPQif #NGS  #oncology #precisionmedicine  #targetedtherapy  #Geneseeq #ctDNA #MRD